Ascom announces visionary platform for data-driven era of healthcare


Ascom Holding AG / Ascom announces visionary platform for data-driven era of healthcare . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

The Ascom Healthcare Platform bridges information gaps to optimize digital workflows and meet the demands of clinical care


BAAR, Switzerland, March 05, 2018 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), a global solutions provider focused on healthcare ICT and mobile workflows, announces today in Las Vegas at HIMSS, Booth #4212, a new approach to delivering optimized digital clinical information flows with the Ascom Healthcare Platform. Delivering integrated and orchestrated clinical workflow solutions, the Ascom Healthcare Platform closes digital information gaps between devices, hospital systems and clinical care teams to extend the reach of critical information across points of care and enable informed, timely clinical decisions.

In today's clinical environments data is everywhere, but timely access to contextually relevant, digital information is still a challenge. Take an ICU patient, for example. In a single day, one ICU patient can generate up to 2,000 data points [1]. But data is just the starting point, clinicians need actionable insight for responsive patient care.

"The Ascom Healthcare Platform addresses the complexity of clinical care. Designed as an open and technology agnostic solution, the Platform takes a multi-dimensional approach to clinical workflows and digital information flows. By creating interoperability between existing medical devices, healthcare information systems and care management solutions, clinical care information becomes more insightful, accessible and actionable. And the benefits are tangible, including fewer instances of miscommunication, preventing double documentation errors, improving patient response time and increasing time available for patient care," comments Francis Schmeer, Ascom EVP Marketing & Business Development.

The Ascom Healthcare Platform is a distinct approach to delivering workflow digitization, workflow optimization as well as analytics and smart data.

  • Consulting teams work with hospitals to provide customized, interoperable, modular and scalable solutions from design, to implementation, integration and support.
  • Workflow Orchestration solutions streamline, filter and prioritize alerts and task notifications while extending the flow of information to mobile clinical care teams for more responsive and informed care communication and collaboration.
  • Analytics and smart data applications add and enable delivery of structure and clinical context to information, helping clinicians and care teams coordinate care to address patient needs. 

Together with Ascom's solution leadership in clinical orchestration software and applications from Digistat and Unite; Patient Response and Workflow Systems from Telligence and Mobility from the Myco smart device portfolio, the Ascom Healthcare Platform enables optimized clinical workflows from simple to complex. Across general wards, operating rooms and ICUs, Ascom enables care team coordination and collaboration; bedside vital signs registration; early warning scores, ICU central monitoring; medical asset management; operating room patient management systems and more. 

"The Ascom Healthcare Platform is the realization of a powerful vision, where digital clinical information is connected, optimized and accessible to clinicians, from the point of care to anywhere. Because the challenges around clinical data are vast and complex, we set out to bring together mobile clinical workflow technology and solutions to create a dynamic proposition that is both powerful and flexible. As we continue to innovate, the platform expands upon our market leadership in mobile workflows by bridging gaps and unlocking the full value of digital clinical information across points of care from general wards to operating rooms and Intensive Care Units and across care teams, when and where they need it most," says Holger Cordes, CEO of Ascom.


Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions - anytime and anywhere. Ascom's mission is to provide mission-critical, real-time solutions for highly mobile, ad hoc, and time-sensitive environments. Ascom uses its unique product and solutions portfolio and software architecture capabilities to devise integration and mobilization solutions that provide truly smooth, complete and efficient workflows for healthcare as well as for industry and retail sectors.

Ascom is headquartered in Baar (Switzerland), has operating businesses in 18 countries and employs around 1,300 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich.

Multiple products from Ascom and third parties support the features and functions described herein. All Ascom solutions may not be available in specific countries.

[1] McFarling, Usha Lee. Raising an alarm, doctors fight to yank hospital ICUs into the modern era. Stat, 7 September 2016.

Ascom Group Media Office, Daniel Lack, Legal & Communications/IR

+41 41 544 78 10,

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ascom Holding AG via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00Pressmeddelande

End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to

McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions20.3.2018 09:03Pressmeddelande

Company Expected to Prevent 150 Million Metric Tons of Emissions by 2030 OAK BROOK, Ill., March 20, 2018 (GLOBE NEWSWIRE) -- Today, McDonald's announces it will partner with franchisees and suppliers to reduce greenhouse gas emissions related to McDonald's restaurants and offices by 36% by 2030 from a 2015 base year in a new strategy to address global climate change. Additionally, McDonald's commits to a 31% reduction in emissions intensity (per metric ton of food and packaging) across its supply chain by 2030 from 2015 levels. This combined target has been approved by the Science Based Targets initiative(SBTi). Through these actions, McDonald's expects to prevent 150 million metric tons of greenhouse gas emissions from being released into the atmosphere by 2030. This is the equivalent of taking 32 million passenger cars off the road for an entire year or planting 3.8 billion trees and growing them for 10 years. The target will enable McDonald's to grow as a business without growing it

Momentum Group acquires Reklamproffsen in Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) has acquired 70 percent of the shares in Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen is a leading reseller of promotional products, including workwear and profile clothing, in Örebro and the surrounding area. Reklamproffsen generates annual revenue of approximately MSEK 35 with favourable profitability and has 12 employees. Reklamproffsen is one of Örebro's largest resellers of workwear and profile clothing, with a high level of expertise in customising company products. Reklamproffsen has a professional store and showroom in Örebro. Its customers mainly comprise industrial and service companies, and a significant portion of its sales are conducted via customised online stores. "Thanks to its strong customer and supplier relationships and highly skilled employees, Reklamproffsen has achieved successful growth since it was formed in 2000. It is now a well-established company in Örebro and the surrounding area. We anticipate good opportuniti

Momentum Group förvärvar Reklamproffsen i Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) har förvärvat 70 procent av aktierna i Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen är en ledande återförsäljare av produktmedia innefattande yrkeskläder och profilkläder i Örebro med omnejd. Reklamproffsen omsätter cirka 35 MSEK per år med god lönsamhet och har 12 anställda. Reklamproffsen är en av Örebros största återförsäljare inom yrkeskläder och profilkläder med hög kompetens inom företagsprofilering. Reklamproffsen har en yrkesbutik och utställning i Örebro. Kunderna utgörs främst av industri- och serviceföretag och en betydande andel av försäljningen sker via kundunika webbshoppar. - Reklamproffsen har med sina starka kund- och leverantörsrelationer och medarbetare med hög kompetens utvecklats framgångsrikt ända sedan starten år 2000. Bolaget är idag ett väletablerat företag i Örebro med omnejd. Vi ser mycket goda möjligheter till vidare utveckling och tillväxt för Reklamproffsen som en del av Momentum Group, säger Ulf Lilius, VD & K

Immunicum AB: Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data20.3.2018 08:00Pressmeddelande

Press Release 20 March 2018 Immunicum AB (publ) Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that its lead product candidate, ilixadencel, has been granted an Advanced Therapy Medicinal Product (ATMP) certificate following a review of manufacturing quality and non-clinical data by the European Medicines Agency (EMA). "The EMA ATMP certificate is an important development milestone for ilixadencel because it validates our manufacturing quality and preclinical data and gives us a firm foundation for the later stages of clinical development. Cell-based therapies must meet very high requirements and we are pleased to have this recognition from the EMA of our work to date," said Carlos de Sousa, CEO of Immunicum. "Immunicum is one of very few companies that have successfully u

Immunicum AB: Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data20.3.2018 08:00Pressmeddelande

Pressmeddelande 20 mars 2018 Immunicum AB (publ) meddelar att ilixadencel har beviljats ATMP-certifiering från EMA gällande tillverkningskvalitet och prekliniska data Immunicum AB (publ; IMMU.ST) ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelar idag att bolagets ledande produktkandidat, ilixadencel, har erhållit en ATMP-certifiering (Advanced Therapy Medicinal Product) efter granskning av tillverkningskvalitet och prekliniska data av den europeiska läkemedelsmyndigheten EMA (European Medicines Agency). "EMAs ATMP certifikat är en viktig milstolpe i utvecklingen av ilixadencel eftersom det validerar vår tillverkningskvalitet och våra prekliniska data, och ger oss samtidigt en solid bas för de senare faserna i den kliniska utvecklingen. Cell-baserade terapier måste uppfylla mycket höga krav och vi är glada att få detta erkännande av EMA för vårt arbete så här långt," säger Carlos de Sousa, VD för Immunicum. "Immunicum ä

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum